Navigation Links
HSP90: New point of view on melanoma of the eye, at the MUHC
Date:2/19/2008

Montreal, 19 February, 2008 - Ocular melanoma is rarely detected before it has grown large enough to impair vision or to metastasize. This makes it a particularly challenging disease to fight, especially since chemotherapy is not very effective.

Now, the PhD research project led by Dr. Dana Faingold may open the door for very promising new treatment options for this pathology. Her first article was featured on the cover of the February 2008 issue of Clinical Cancer Research.

The first step in developing a medication is to determine the precise target of action, explained Dana Faingold. In this study, we have shown that to effectively fight this malignant tumour in the vascular network of the eye, we had to target Heat Shock Protein 90 (HSP90).

HSP90 is already a therapeutic target in many other types of cancer. In fact, this protein, which is called a chaperone because it guides the actions of other proteins, is at the centre of many metabolic pathways. By disrupting HSP90s functioning, it is possible to affect multiple steps in cell metabolism, for example, signalling pathways, cell cycle regulation pathways, or growth hormone receptors. This blocks many vital cellular functions, so the cancer cells become unable to reproduce and the tumour regresses.

Clinical trials are currently being conducted to determine the effectiveness of an antibiotic called 17/AAG, an HSP90 inhibitor, against malignant tumours of the skin, breast and in patients with multiple cancers. However, no one has yet studied this inhibitors effect on ocular melanoma. This is a pre-clinical study, which means we are examining in-vitro cell lines. Our results clearly prove not only that HSP90 is largely overexpressed in this type of tumour but also that the 17/AAG molecule is effective at reducing the growth of these tumoral cells, said Dana Faingold.

Several clinical trial stages will have to be completed before 17/AAG can be recognized as a possible treatment for melanoma of the eye. The first stage, which should begin shortly, aims at proving the effectiveness of the molecule in an animal model. This in vivo confirmation is necessary before testing for human treatment can begin.


'/>"/>

Contact: Isabelle Kling
isabelle.kling@muhc.mcgill.ca
514-934-1934
McGill University Health Centre
Source:Eurekalert

Related medicine news :

1. Study Points to Cause of Vioxx Heart Risk
2. NYU study points to lasting impact of mild hearing loss on neurological processes
3. WorldHeart Appoints David Pellone Chief Financial Officer
4. Novo Nordisk Appoints New Leader of North American Business
5. WellPoint Announces Appearances at Upcoming Conferences
6. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
7. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
8. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
9. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
10. Resonant Medical Appoints New Vice President of Global Sales
11. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research ... Electrodes Market Analysis and Trends - Adhesion Type, Application, Usability - ... ... The Global Cardiology Electrodes Market is poised to grow at a ... prominent trends that the market is witnessing include advancements in extracellular ...
(Date:12/8/2016)... 8, 2016   TriNetX , the health ... Hospital signed a membership agreement to join ... of new cures. The TriNetX network ... million patients globally, biopharmaceutical companies and contract research ... protocol design, site selection, patient recruitment, and collaborative ...
Breaking Medicine Technology: